Featured on SDSU News Center: SDSU Researcher Works to Combat Drug Resistance
A $6.1M grant aims to determine how tuberculosis becomes resistant to drugs and develop prognostic and diagnostic tools to help patients
Join our lab!
We are currently accepting Master's and PhD students. We also have an open postdoctoral position. For more information, visit the links below:
Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence
Led by Dr. Faramarz Valafar, we are an NIH funded laboratory through the National Institute for Allergy and Infectious Diseases (NIAID).
We study the genetic (including dark genetic matter), epigenetic, metagenomic bases for treatment failure in infectious diseases. This includes study of evolutionary path and emergence of enhanced antibiotic resistance, virulence, fitness, and host pathogen interactions.
Our primary project focuses on tuberculosis (TB), which recently surpassed HIV/AIDS as the infectious disease causing the highest mortality. Over 10 million people develop the active form of the disease and 1.5 million people die from it annually. Antibiotic resistance in Mycobacterium tuberculosis (Mtb), the causative agent of TB, is a serious threat to the World Health Organization’s efforts in global TB control. In some parts of the world, 75% of all active TB cases are multi-drug resistant.
Our funding provides support for our research projects in San Diego and collaborations with seven international sites in Stockholm, Antwerp, Minsk, Cape Town, Mumbai, Riga, and Chisinau. In collaboration with hospitals and public health agencies in these cities, we study the emergence and mechanisms of antibiotic resistance, virulence, fitness, and the molecular basis for other clinically relevant phenotypes in Mtb.